Saketh Ram Thrigulla

Saketh Ram Thrigulla

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Ayurveda and Integrative Medicine
Verified
Journal Article
Open access
STSaketh Ram Thrigulla
Saketh Ram Thrigulla
MMManne Munikumar
Manne Munikumar
VRVankudavath Naik Raju
Vankudavath Naik Raju
PDParasannanavar Devaraj
Parasannanavar Devaraj
NBNaveen Kumar Boiroju
Naveen Kumar Boiroju
KDK.S. Dhiman
K.S. Dhiman
Outbreak of Corona Virus Disease in late 2019 (COVID-19) has become a pandemic global Public health emergency. Since there is no approved anti-viral drug or vaccine declared for the disease and investigating existing drugs against the COVID-19. AYUSH-64 is an Ayurvedic formulation, developed and patented by Central Council of Research in Ayurvedic Sciences, India, has been in clinical use as anti-malarial, anti-inflammatory, anti-pyretic drug for few decades. Thus, the present study was undertaken to evaluate AYUSH-64 compounds available in this drug against Severe Acute Respiratory Syndrome-Corona Virus (SARS-CoV-2) Main Protease (Mpro; PDB ID: 6LU7) via in silico techniques. Different molecular docking software’s of Discovery studio and Auto Dock Vina were used for drugs from selected AYUSH-64 compounds against SARS-CoV-2. We also conducted 100 ns period of molecular dynamics simulations with Desmond and further MM/GBSA for the best complex of AYUSH-64 with Mpro of SARS-CoV-2. Among 36 compounds of four ingredients of AYUSH-64 screened, 35 observed to exhibits good binding energies than the published positive co-crystal compound of N3 pepetide. The best affinity and interactions of Akuammicine N-Oxide (from Alstonia scholaris) towards the Mpro with binding energy (AutoDock Vina) of -8.4 kcal/mol and Discovery studio of Libdock score of 147.92 kcal/mol. Further, molecular dynamics simulations with MM-GBSA were also performed for Mpro– Akuammicine N-Oxide docked complex to identify the stability, specific interaction between the enzyme and the ligand. Akuammicine N-Oxide is strongly formed h-bonds with crucial Mpro residues, Cys145, and His164. The results provide lead that, the presence of Mpro– Akuammicine N-Oxide with highest Mpro binding energy along with other 34 chemical compounds having similar activity as part of AYUSH-64 make it a suitable candidate for repurposing to management of COVID-19 by further validating through experimental, clinical studies.

1 April 2023 in International Journal of Ayurveda Research
Verified
Journal Article
Open access
STSaketh Ram Thrigulla
Saketh Ram Thrigulla
Innovative use of Information Communication Technology in the Ayush sector enables achieving Universal Health Coverage (UHC), health emergency protection, and healthier populations in the integrative health-care acumen. Ayush Grid (AG) is an Ayush-centric Digital Health Platform (DHP) created by the Ministry of Ayush, Government of India in the year 2018. It works in sync with the Ayushman Bharat Digital Mission (ABDM)-India's national digital health infostructure platform. The components of the AG cover all the verticals of the Ayush Sector, namely Health Services, Education, Ayush Research, Central Sector and Centrally Sponsored Schemes, Training Programmes, Citizen Centric Services, Drug Licencing Portal, and Media Outreach through four distinct layers namely The core layer, National Layer, State Layer, and Citizen access. The significant contributions of AG so far are the implementation and maintenance of the National Ayush Morbidity and Standardized Electronic (NAMASTE) portal, Ayush Research Portal, development and implementation of Ayushman Bharat Health Account (ABHA) enabled Ayush Hospital Information Management System (AHMIS), Ayush Sanjivani app (during COVID-19 pandemic), assisting the World Health Organization (WHO) in the development of mYoga app, Ayurveda Siddha and Unani International terminologies and morbidity codes (as Module-2, Chapter-26, ICD-11), development of benchmarks for the use of Artificial Intelligence (AI) in the field of traditional medicine under the “Artificial Intelligence for Health (AI4Health)” initiative by the International Telecommunication Union (ITU) and WHO, etc. The paper discusses the role of AG as an enabler to integrate Ayush systems in the national and international health-care setting.

2 August 2023 in Journal of Ayurveda and Integrative Medicine
Verified
Journal Article
Open access
STSaketh Ram Thrigulla
Saketh Ram Thrigulla
Narayanam SrikanthNarayanam Srikanth
Narayanam Srikanth

1 July 2022 in AYU (An International Quarterly Journal of Research in Ayurveda)
Verified
Journal Article
Open access
STSaketh Ram Thrigulla
Saketh Ram Thrigulla
VSV. Sridevi
V. Sridevi
BKB. Vamshi Krishna
B. Vamshi Krishna
MNM. Karthik Naik
M. Karthik Naik
KDK. Rudrama Devi
K. Rudrama Devi
Narayanam SrikanthNarayanam Srikanth
Narayanam Srikanth
Bibliometric analysis is a standard method for evaluating the quality and quantity of published articles. AYUSH research portal (ARP) is meant for the dissemination of research findings in the domains of Ayurveda, Yoga and Naturopathy, Unani, Siddha, Sowa-rigpa, and Homoeopathy and allied faculties. The study attempts to understand the trend of published Ayurveda clinical trial-based articles in terms of quality and quantity. Three perspectives of research output assessed in this study are productivity in the field of Ayurveda, evidence from articles, and its involvement with the body system where disease or malfunctions are induced. Based on the study, it is observed that the highest number of articles have been published under the musculoskeletal, endocrine/metabolic/nutritional categories, and skin. Further, it is observed that only 4.50% of articles are categorized under the evidence of Grade “A” (randomized controlled trials [RCTs]) as per the World Health Organization’s traditional medicine research guidelines. Out of the top 20 journals which publish Ayurveda-based research works, only five journals are indexed in reputed indexing platforms viz., PubMed and Scopus. The findings indicate that, Ayurveda clinical trials have to be planned meticulously and carried out as per the RCT guidelines for producing quality evidence so that the abysmal percentage of grade-A category articles will increase in ARP. Further, the journals, which are not yet indexed in standard indexing platforms, must strive to secure a place in them to ensure access to appropriate peers and effective dissemination of findings.

27 May 2024 in Journal of Ayurveda and Integrative Medicine
Verified
Journal Article
Open access
STSaketh Ram Thrigulla
Saketh Ram Thrigulla
GSGagandeep Singh
Gagandeep Singh
HSHemant Soni
Hemant Soni
STSmriti Tandon
Smriti Tandon
SKShruti Koulgi
Shruti Koulgi
RARabinarayan Acharya
Rabinarayan Acharya
Shyonaka (Oroxylum indicum Vent) is widely used in Ayurveda and in ethnomedical practice for the treatment of inflammation, pain, diarrhea, non-healing ulcers, and cancer. Owing to the high prevalence of Epstein-Barr virus (EBV) infection in Nasopharyngeal carcinoma (NPC) patients, simultaneous targeting of proteins involved in both EBV replication and NPC proliferation might help to manage the disease effectively. This study is designed to identify potential dual targeting inhibitors from Oroxylum indicum having the potential to inhibit both EBV and NPC. This study also attempted quantitative analysis of Shyonaka Bark Decoction (SBD) to confirm the presence of Baicalein and Chrysin which are predominant marker compounds of Shyonaka. The HPLC analysis of stem bark and root bark of Oroxylum indicum was done to estimate the presence of marker compounds Baicalein and Chrysalin. The in-silico analysis included ADMET analysis followed by molecular docking of known compounds from Oroxylum indicum (retrieved from IMPPAT database) onto the target proteins of EBV (BHRF1, NEC1, dUTPase, Uracil DNA glycosylase) and NPC (COX-2, EGFR, and MDM2) using DOCK6 tool. Further validations were done using the molecular dynamics simulations of top screened molecules onto the selected target proteins using AMBER20 package and their corresponding MMGBSA binding free-energy values were calculated. The molecular docking revealed that the key molecules from the plant, scutellarein 7-rutinoside (S7R), scutellarin (SCU) and 6-hydroxyluteolin, Baicalein and 5,7-Dihydroxy-2-phenyl-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one (57D) are effectively intervening with the target proteins of EBV, one of the key causative factors of NPC and the NPC specific targets which have the potential to reduce tumor size and other consequences of NPC. The molecular dynamics simulations of S7R, Baicalein and 57D, Baicalein with MDM-2 protein and dUTPase protein, respectively, showed stable interactions between them which were further assessed by the binding energy calculations. Overall, the in-silico evaluation of these phytochemicals with target proteins indicates their potential to inhibit both EBV and NPC which needs further in-vitro and in-vivo validations.

19 March 2021 in OSF Preprints
Verified
Preprint
Open access
Narayanam SrikanthNarayanam Srikanth
Narayanam Srikanth
RRRakesh Kumar Rana
Rakesh Kumar Rana
SJSophia Jameela
Sophia Jameela
RSRicha Singhal
Richa Singhal
ATArunabh Tripathi
Arunabh Tripathi
KDKartar Singh Dhiman
Kartar Singh Dhiman
AYUSH Sanjivani is a mobile application launched by the Ministry of AYUSH (MoA) to gather information regarding the utilization of AYUSH (Ayurveda, Yoga, Unani, Siddha, and Homeopathy) advocacies for the prevention of COVID-19 infection. A cross-sectional analysis of the data generated through this mobile application has been performed and presented in this article to examine the acceptability and extent of utilization of AYUSH preventive measures in India.Objectives: The objectives of this cross-sectional analysis was to determine the trends of the utilization of AYUSH measures by the beneficiaries as reported by AYUSH practitioners and by the practitioners themselves for the prevention of COVID-19 and to determine the benefit obtained in terms of self-reported parameters of general well being, the overall impact on general health and in preventing the onset of flu-like symptoms.Methods: A secondary data analysis was undertaken, utilizing the cross-sectional data generated through the AYUSH Sanjivani App from May to July 2020. The responses in terms of demographic profile, utilization pattern, benefits obtained, the interventions used and the data of beneficiaries in terms of geographic location and interventions prescribed were analyzed statistically to assess the trends of the utilization of AYUSH measures for prophylaxis.Results: Data of 74,568 AYUSH physicians and 1,35,21,245 beneficiaries/health seekers whose data were reported by 3623 AYUSH practitioners were used for analysis. AYUSH advocacies/measures were utilized by 69,195 (92.8%) physicians for prophylaxis. Samshamani Vati, Chyavanprash, and Arsenicum Album-30 were the most commonly used AYUSH interventions. Improvement in terms of appetite, bowel movements, sleep, mental well being, stamina, change in pre-existing disease, and change in disposition were reported by 42400 (61.3%) physicians. Maximum beneficiaries were from the state of Gujarat followed by Madhya Pradesh. Arsenicum Album-30 was the most commonly prescribed/distributed intervention among the beneficiaries/ health seekers.Conclusion: Maximum physicians have reported having benefited from the use of AYUSH prophylactic measures for the prevention of COVID-19. Moreover, a good proportion of the Indian population was provided the AYUSH prophylactic measures as recorded in the app.